A PRC2-independent function for EZH2 in regulating rRNA 2′-O methylation and IRES-dependent translation
Dysregulated translation is a common feature of cancer. Uncovering its governing factors and underlying mechanism are important for cancer therapy. Here, we report that enhancer of zeste homologue 2 (EZH2), previously known as a transcription repressor and lysine methyltransferase, can directly inte...
Saved in:
Published in | Nature cell biology Vol. 23; no. 4; pp. 341 - 354 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.04.2021
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Dysregulated translation is a common feature of cancer. Uncovering its governing factors and underlying mechanism are important for cancer therapy. Here, we report that enhancer of zeste homologue 2 (EZH2), previously known as a transcription repressor and lysine methyltransferase, can directly interact with fibrillarin (FBL) to exert its role in translational regulation. We demonstrate that EZH2 enhances rRNA 2′-
O
methylation via its direct interaction with FBL. Mechanistically, EZH2 strengthens the FBL–NOP56 interaction and facilitates the assembly of box C/D small nucleolar ribonucleoprotein. Strikingly, EZH2 deficiency impairs the translation process globally and reduces internal ribosome entry site (IRES)-dependent translation initiation in cancer cells. Our findings reveal a previously unrecognized role of EZH2 in cancer-related translational regulation.
Yi et al. report that EZH2 exerts a PRC2-independent function in nucleoli, where it bridges FBL and NOP56 to facilitate rRNA methylation and subsequent IRES-dependent translation. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author Contributions Y.Y. and Q.C. conceived and designed the research with the help of W.Z.; Y.Y. performed a majority of the experiments with assistance from Q.M., Q.L., F.L., B.L., A.S., Q.L., Z.J. and L.W.; C.L., W.J., R.W. and Q.L. performed mouse xenograft studies; L.F. and X.D. performed the IHC and PLA assays; J.S. performed the BS3 crosslinking assay under supervision of H.N.; W.Q. conducted the TEM assay; S.K. provided control and EZH1/EZH2 double-knockout XEN cells; Y.Y. and Q.M. performed the next-generation sequencing; A.B.W. conducted the gene expression and survival analyses using JHMI cohort under supervision of T.L.L. and E.M.S.; Y.L. and D.Z. conceived, designed, and performed bioinformatics analysis under supervision of K.C.; Y.Y. and Q.C. wrote the paper; All authors discussed the results and commented on the manuscript. |
ISSN: | 1465-7392 1476-4679 |
DOI: | 10.1038/s41556-021-00653-6 |